Talzenna, also known by its generic name talazoparib, has its primary patent protection set to expire in 2029 [1]. This expiration date pertains to the compound patent for talazoparib.
What is Talzenna used for?
Talzenna is a PARP inhibitor used to treat certain types of advanced breast cancer, specifically HER2-negative locally advanced or metastatic breast cancer with a germline BRCA mutation [2].
When does Talzenna's market exclusivity end?
Beyond the compound patent, other forms of exclusivity can impact market entry. These may include data exclusivity, which is granted upon drug approval and lasts for a set period, and any additional patents covering specific formulations, methods of use, or manufacturing processes [3]. The interplay of these patent and exclusivity periods dictates when generic or biosimilar versions can be legally marketed.
Can generics enter the market before patent expiry?
The entry of generic versions of a drug is typically contingent on patent expiry and the successful navigation of regulatory pathways, such as the Hatch-Waxman Act in the United States. Challenges to existing patents can also alter the timeline for generic competition [4]. DrugPatentWatch.com tracks these patent landscapes and potential litigation that could affect market exclusivity [1].
What are the risks of challenging drug patents?
Companies that challenge drug patents, often in pursuit of launching generic alternatives, face significant risks. These include lengthy and expensive litigation, the possibility of losing the challenge and incurring legal costs, and potential delays in market entry if the patent is upheld [4].
How does talazoparib work?
Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor. PARP enzymes are involved in DNA repair. By inhibiting PARP, talazoparib prevents cancer cells with specific DNA repair deficiencies, such as those with BRCA mutations, from repairing damaged DNA, ultimately leading to cell death [2].
Who makes Talzenna?
Talzenna is developed and marketed by Pfizer [2].
What are the side effects of Talzenna?
Common side effects of Talzenna include anemia, fatigue, nausea, headache, and decreased appetite. More serious side effects can include bone marrow suppression and the potential for secondary malignancies [2].
What are the treatment alternatives for BRCA-mutated breast cancer?
Other PARP inhibitors, such as olaparib, are also used to treat HER2-negative, germline BRCA-mutated breast cancer. Treatment decisions are individualized based on disease stage, patient history, and specific genetic mutations [2].
---
Sources:
1. DrugPatentWatch.com
2. U.S. Food & Drug Administration (FDA)
3. Generic Pharmaceutical Association (GPhA)
4. Hatch-Waxman Act